Table 1 Baseline characteristics of patients who received adequate antibiotic monotherapy and combination therapy, and inadequate therapy
Total (n = 100) | Adequate therapy (n = 65) | Inadequate therapy (n = 35) | Pvalue | ||
|---|---|---|---|---|---|
Monotherapy (n = 32) | Combination therapy (n = 33) | ||||
Age (median years, range) | 59 (53–67) | 60 | 56 | 61 | 0.24 |
Male gender | 74 (74.0) | 27 (84.4) | 24 (72.7) | 23 (65.7) | 0.22 |
Underlying disease | |||||
Hematologic malignancy | 34 (34.0) | 12 (37.5) | 14 (42.4) | 8 (22.9) | 0.21 |
Solid organ malignancy | 23 (23.0) | 8 (25.0) | 12 (36.4) | 3 (8.6) | 0.02 |
Neurologic disease | 14 (14.0) | 7 (21.9) | 0 | 7 (20.0) | 0.01 |
Immunosuppression | 22 (22.0) | 6 (18.8) | 10 (30.3) | 6 (17.1) | 0.13 |
Structural lung disease | 8 (8.0) | 2 (6.3) | 4 (12.1) | 2 (5.9) | 0.65 |
Congestive heart failure | 9 (9.0) | 2 (6.3) | 1 (3.0) | 6 (17.1) | 0.13 |
Hemodialysis | 10 (10.0) | 2 (6.3) | 1 (3.0) | 7 (20.0) | 0.07 |
Liver cirrhosis | 5 (5.0) | 1 (3.1) | 2 (6.1) | 2 (5.7) | 0.99 |
Biliary disease | 2 (2.0) | 0 | 0 | 2 (5.7) | 0.33 |
McCabe score | <0.001 | ||||
Non-fatal | 42 (42.0) | 13 (40.6) | 7 (21.2) | 22 (62.9) | |
Ultimately fatal | 44 (44.0) | 18 (56.3) | 20 (60.6) | 6 (17.1) | |
Rapidly fatal | 14 (14.0) | 1 (3.1) | 6 (18.2) | 7 (20.0) | |
APACHE II score, median (IQR) | 21 (16–26) | 18.5 (13–22) | 20 (17–24.5) | 23 (14–27) | 0.08 |
Pitt bacteremia score, median (IQR) | 3 (1–5) | 2 (0–4) | 3 (2–5) | 4 (2–6) | 0.05 |
CPIS, median (IQR) | 6 (5–7) | 6 (5–7) | 6 (5–7) | 6 (5–7) | 0.57 |
Type of pneumonia | 0.01 | ||||
Community-acquired | 18 (18.0) | 3 (9.4) | 11 (33.3) | 4 (11.4) | |
Healthcare-associated | 19 (19.0) | 8 (25.0) | 6 (18.2) | 5 (14.3) | |
Hospital- acquired | 44 (44.0) | 15 (46.9) | 15 (45.5) | 14 (40.0) | |
Ventilator-associated | 19 (19.0) | 6 (18.8) | 1 (3.0) | 12 (34.3) | |
Initial manifestation within 24 h | 0.22 | ||||
Bacteremia without SIRS | 6 (6.0) | 2 (6.3) | 2 (6.1) | 2 (5.7) | |
Sepsis | 35 (35.0) | 17 (53.1) | 8 (24.2) | 10 (28.6) | |
Severe sepsis | 21 (21.0) | 6 (18.8) | 7 (21.2) | 8 (22.9) | |
Septic shock | 38 (38.0) | 7 (21.9) | 16 (48.5) | 15 (42.9) | |
MDR- P. aeruginosa | 23 (23.0) | 6 (18.8) | 2 (6.1) | 15 (42.9) | 0.001 |
Previous antibiotic therapy | 55 (55.0) | 17 (30.9) | 11 (20.0) | 27 (49.1) | 0.009 |
Initial antimicrobial administration within 24 h | 94 (94.0) | 29 (90.6) | 32 (96.9) | 33 (94.3) | 0.60 |
Total duration of therapy, median days (IQR) | 14 (8–21) | 15 (9–19) | 14 (8–22) | 14 (7–21) | 0.71 |
Total length of hospital stay, median days (IQR) | 37.5 (19–75) | 39 (19–94) | 28 (13–60) | 52 (26–82) | 0.10 |
Length of hospital stay before bacteremia, median days (IQR) | 12.5 (0–39) | 9 (0–29.5) | 0 (0–19.5) | 29 (9–59) | 0.005 |
Length of hospital stay after bacteremia, median days (IQR) | 16.5 (7–36.5) | 18.5 (10.8-52.5) | 16 (6.5-34) | 17 (7–33) | 0.21 |
Overall mortality | |||||
7-day mortality | 21 (21.0) | 5 (15.6) | 6 (18.2) | 10 (28.6) | 0.382 |
14-day mortality | 30 (30.0) | 8 (25.0) | 6 (18.2) | 16 (45.7) | 0.035 |
28-day mortality | 51 (51.0) | 17 (53.1) | 10 (30.3) | 24 (68.6) | 0.01 |